March 5, 2026 Corporate Presentation 2.4 MB April 1, 2025 COMPANION-002 Data Disclosure 985.8 KB April 17, 2024 Survey of CTX-009 Patient Selection Hypotheses Using Real World Biliary Tract Cancer Data 1.4 MB April 17, 2024 Introduction of CTX-009 and COMPANION-002 Study 722.2 KB April 9, 2024 The Combination of DLL4/VEGF-A Blockage and Immunomodulation Can Eliminate MHC Class I Negative Tumors in Mice 745.8 KB January 23, 2023 CTX-009 Phase 2 Results in BTC Presented at ASCO GI Presentation 1.1 MB April 11, 2022 2022 AACR Annual Meeting Presentation 2.5 MB
April 17, 2024 Survey of CTX-009 Patient Selection Hypotheses Using Real World Biliary Tract Cancer Data 1.4 MB
April 9, 2024 The Combination of DLL4/VEGF-A Blockage and Immunomodulation Can Eliminate MHC Class I Negative Tumors in Mice 745.8 KB
The Combination of DLL4/VEGF-A Blockage and Immunomodulation Can Eliminate MHC Class I Negative Tumors in Mice 745.8 KB